Gapping down
In reaction to disappointing earnings/guidance:
In reaction to disappointing earnings/guidance:
- N/A
M&A news:
- EQT -5.4% (Rice Energy (RICE) and EQT acquisition confirmed for total consideration of ~$6.7 billion)
Other news:
- SGEN -11.7% (discontinuing the phase 3 CASCADE clinical trial of vadastuximab talirine)
- TSRO -11.3% (after CLVS reported positive topline data from the confirmatory phase 3 ARIEL3 trial of rucaparib; PARP competitor Tesaro trading lower in response)
- LTBR -3.2% (files for 1,853,960 share common stock offering by Aspire Capital Fund)
Analyst comments:
- PI -3.1% (downgraded to Equal-Weight from Overweight at Morgan Stanley)
- TRIP -2.1% (downgraded to Underperform from Neutral at Credit Suisse)
- LYV -1.3% (downgraded to Neutral from Buy at Northcoast)
- IHG -1.3% (downgraded to Neutral from Outperform at Credit Suisse)